Last reviewed · How we verify
Boostrix ® Polio
Boostrix Polio is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus.
Boostrix Polio is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | Boostrix ® Polio |
|---|---|
| Also known as | dTPa-IPV vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens. This provides immunological protection against diphtheria, tetanus, whooping cough, and poliomyelitis.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults
Common side effects
- Injection site pain
- Injection site redness
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa (PHASE4)
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (PHASE3)
- Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
- Gambia Pertussis Study (GaPs) (PHASE4)
- Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (PHASE4)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boostrix ® Polio CI brief — competitive landscape report
- Boostrix ® Polio updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI